AzTrials
AzTrials

Shoulder Impingement SyndromeNCT07113639

Effectiveness of High-Volume Corticosteroid Injection in Shoulder Impingement

A study testing Injection in people with Shoulder Impingement Syndrome, run by TC Erciyes University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to compare the effectiveness of high-volume versus low-volume ultrasound-guided corticosteroid injections diluted with saline in patients with subacromial impingement syndrome, finding no significant difference in pain or functional outcomes between the two methods. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Shoulder Impingement Syndrome
What is being tested?
Injection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Oct 2020to 1 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of subacromial impingement syndrome (SIS)
  • Age over 18 years
  • Shoulder pain lasting longer than 4 weeks
  • Shoulder pain with a visual analogue scale (VAS) score of 3 or higher
  • Passive shoulder range of motion within normal limits

Who cannot join

  • Full-thickness tear or calcification of the rotator cuff in the affected shoulder
  • Adhesive capsulitis
  • History of trauma or surgery in the affected shoulder
  • History of injection into the affected shoulder within the previous 6 months
  • History of systemic rheumatic disease, malignancy, or coagulopathy
  • Suspected cervical radiculopathy
  • History of allergy to local anesthetics (LA) and/or corticosteroids (CS)

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Erciyes University Faculty of Medicine Hospital

    Kayseri, 38100

Other trials in Turkey (Türkiye)

About this study

Official title: Effectiveness of High-volume Corticosteroid Injection Diluted With Saline in Subacromial Impingement Syndrome: A Prospective Randomized Trial

This study aimed to compare the effectiveness of high-volume versus low-volume ultrasound-guided corticosteroid injections diluted with saline in patients with subacromial impingement syndrome, finding no significant difference in pain or functional outcomes between the two methods.

Read the detailed description

Subacromial impingement syndrome (SIS) is commonly treated conservatively with corticosteroid (CS) injections into the subacromial bursa, often combined with local anesthetics (LA). Despite widespread use, there remains no consensus regarding the optimal injection technique, volume, or drug formulation. Some studies suggest high-volume injections may provide superior pain relief, while others show no significant difference. To clarify this, a prospective, double-blind, randomized controlled trial was designed to compare the efficacy and safety of high-volume versus low-volume CS injections in patients with SIS.

Material and methods:

This study is a prospective, double-blind, randomized controlled trial. The study procedure was discussed with the patients, and each participant provided written informed consent.

All patients who were admitted to the outpatient clinic with unilateral shoulder pain within the study period, were screened to assess eligibility for the study The following 3-step checklist was completed for an accurate diagnosis of SIS: history of anterolateral arm pain and exacerbation of symptoms upon raising the shoulder to 90° or higher, a combination of the Neer test, Hawkins-Kennedy test, painful-arc test, and infraspinatus muscle test produced at least 2 positive results and confirmation of the diagnosis by an ultrasound (US) evaluation of the affected shoulder.

The same physiatrist (who had 5 years of experience in musculoskeletal US) performed the complete standard US evaluation of the affected shoulder in each patient, according to the EURO-MUSCULUS/USPRM shoulder scanning protocol. All patients also underwent dynamic US evaluation for SIS . A 3-16-mHz linear probe was used in B mode (Samsung HM70A Plus, Seoul, South Korea). For the US diagnosis of SIS, the subacromial-subdeltoid bursa must have been thicker than 2 mm (bursitis) and a sign of impingement must have been seen on the dynamic evaluations. Any pathological abnormalities associated with SIS (tendinosis, partial-thickness rotator cuff tear, etc.) were also noted.

Outcome Measures:

Detailed in the Outcome Measurements section.

Randomization and blinding After baseline assessment, patients were randomly assigned (1:1) to high-volume (H-VCI) or low-volume (L-VCI) corticosteroid injection groups using computer-generated randomization by an independent secretary. A blinded research assistant prepared the injections. Patients and outcome assessors were blinded to group allocation, but the injector was not blinded due to the differing injection volumes.

Interventions Patients in the H-VCI group received 1 mL of 40 mg triamcinolone acetonide (TA), 1 mL of 2% lidocaine, and 8 mL of normal saline mixture (10 mL total). The patients in the L-VCI group received 1 mL of 40 mg TA, 1 mL of 2% lidocaine, and 1 mL of normal saline mixture (3 mL total).

The physiatrist administered all injections following a standard procedure with US . The patient was taken to the operating room and seated in a chair. The affected arm was placed in the modified Crass position, and the injection site was sterilized and draped. The transducer was placed on the anterosuperior aspect of the shoulder to capture the short axis of the supraspinatus tendon. The subacromial-subdeltoid bursa was visualized between the deltoid muscle and the supraspinatus tendon. Using the in-plane technique, a 21G, 38-mm needle was advanced from lateral to medial to reach the subacromial-subdeltoid bursa. After confirming that the needle tip was inside the bursa, the injectate was administered and its distribution appeared.

Injection-related adverse reactions were monitored and recorded over the following 1-2 h prior to discharge. Following the injections, patients were allowed to take paracetamol (and naproxen 750 mg daily if needed) and were asked to note the dosages that they consumed. Patients were instructed not to take analgesics the day before the follow-up appointment, as this could affect the study results.

All patients were trained once by an experienced physical therapist for a home exercise regimen and were then given a leaflet. The regimen consisted of a combination of range of motion, stretching, scapular stabilization, and rotator cuff resistance exercises. Each patient was instructed to begin this exercise program 4 days after the injection.

Data collection and assessment All patients completed standard questionnaires that collected demographic (age, gender, hand dominance, weight, and height) and current shoulder-pain-related data.

The primary outcome measure was the Shoulder Pain and Disability Index (SPADI) score, which evaluates shoulder pain and disability.

Secondary outcomes included Visual Analog Scale (VAS: pain at night, rest, and movement), Western Ontario Rotator Cuff Index Score (WORC) , and active range of motion (AROM: abduction, flexion, internal/external rotation).

All assessments were performed by a blinded researcher. Evaluations were conducted at baseline, 1 hour, 4 weeks, and 12 weeks post-injection. VAS was assessed at all time points; SPADI, WORC, and AROM were assessed at 4 and 12 weeks.

At 4 and 12 weeks, exercise adherence (never, sometimes, always) was also recorded.

Statistical Analysis Sample size was calculated using G*Power (v3.1.9.4) based on a 10-point minimal clinically important difference in SPADI, with a standard deviation of 14, α = 0.05, and power (β) = 80%, requiring 64 patients. To account for 10% attrition, 70 patients were enrolled.

Analyses were performed using SPSS 22.0 (IBM Corp., Armonk, NY, USA). Data were presented as mean ± SD or median (IQR) for continuous variables, and frequency (%) for categorical variables. Normality was assessed using the Shapiro-Wilk test. Independent t-test or Mann-Whitney U test was used for between-group comparisons, and chi-square test for categorical data.

All outcomes were analyzed based on the intention-to-treat principle, with missing data handled via multiple imputation. Within-group changes were analyzed using the Friedman test. Percent changes from baseline to 4 and 12 weeks were calculated and compared between groups. Post-hoc pairwise comparisons were conducted with the Dunn-Bonferroni test. Statistical significance was set at p < 0.05.

Being tested
Injection
Keywords
shoulder pain, ultrasound, subacromial bursa, injection, different volumes
Medical subject headings
Shoulder Impingement Syndrome, Shoulder Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • InjectionProcedure or surgery

    US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 8 mL normal saline (10 mL total)

  • InjectionProcedure or surgery

    US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 1 mL normal saline (3 mL total)

Study groups in NCT07113639
Study groupRoleWhat they receive
High-Volume Corticosteroid Injection GroupExperimentalUS-guided injection of 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 8 mL normal saline (total volume: 10 mL).
Receives: Procedure: Injection
Low-volume corticosteroid injectionActive comparatorUS-guided injection of 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 1 mL normal saline (total volume: 3 mL)
Receives: Procedure: Injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Shoulder Pain and Disability Index score

    This index assesses shoulder-related pain (5 items) and disability (8 items), for a total of 13 items. Each item is scored from 0 (no pain or difficulty) to 10 (worst pain or very difficult). The score is then converted to a 100-point scale, with higher scores reflecting higher levels of shoulder pain and disability .

    Measured: evaluated at 4 and 12 weeks before injection

Secondary outcomes (3)
  1. Visual Analog Scale (VAS):

    A 100-mm horizontal line is used, with the two extremes of the parameter to be assessed labeled at each end. The patient is asked to indicate their perceived condition by marking a point or drawing a line on the scale that best reflects their current state. VAS is commonly employed to numerically document pain intensity as well as the patient's subjective global health assessment.

    Measured: before injection, 1 hour later, at 4 and 12 weeks

  2. Western Ontario Rotator Cuff Index Score

    The WORC consists of 21 items representing five domains (physical symptoms, sports and recreation, work, lifestyle, and emotions). Each item is scored from 0 to 100 (100 mm VAS). The total score, obtained by summing the scores of all items, is expressed as a percentage of normal. A lower percentage reflects a worse quality of life associated with the affected shoulder.

    Measured: evaluated at 4 and 12 weeks before injection

  3. Active Range of Motion

    active range of motion of the shoulder complex was measured in the supine position using a standard goniometer. These measurements included abduction in the frontal plane, forward flexion, internal rotation, and external rotation with the arm at 90 ° - of abduction.

    Measured: evaluated at 4 and 12 weeks before injection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Aug 2025
  2. Study start1 Oct 2020
  3. Primary completion1 Dec 2021
  4. Study completion1 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07113639
Sponsor's protocol ID
2020-410
Status last verified
Aug 2025
First submitted
4 Aug 2025
Last updated
14 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Boonard M, Sumanont S, Arirachakaran A, Apiwatanakul P, Boonrod A, Kanchanatawan W, Kongtharvonskul J. Short-term outcomes of subacromial injection of combined corticosteroid with low-volume compared to high-volume local anesthetic for rotator cuff impingement syndrome: a randomized controlled non-inferiority trial. Eur J Orthop Surg Traumatol. 2018 Aug;28(6):1079-1087. doi: 10.1007/s00590-018-2149-3. Epub 2018 Feb 8.

    PubMed 29423865
  • Sumanont S, Boonard M, Peradhammanon E, Arirachakaran A, Suwankomonkul P, Oungbumrungpan W, Kongtharvonskul J. Comparative outcomes of combined corticosteroid with low volume compared to high volume of local anesthetic in subacromial injection for impingement syndrome: systematic review and meta-analysis of RCTs. Eur J Orthop Surg Traumatol. 2018 Apr;28(3):397-407. doi: 10.1007/s00590-017-2056-z. Epub 2017 Oct 12.

    PubMed 29027006
  • Ge M, Zhang Y, Li Y, Feng C, Tian J, Huang Y, Zhao T. Publication Trends and Hot Spots in Subacromial Impingement Syndrome Research: A Bibliometric Analysis of the Web of Science Core Collection. J Pain Res. 2022 Mar 28;15:837-856. doi: 10.2147/JPR.S348528. eCollection 2022.

    PubMed 35370418

Questions about this trial

What is this clinical trial studying?

A study testing Injection in people with Shoulder Impingement Syndrome, run by TC Erciyes University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Shoulder Pain and Disability Index score (time frame: evaluated at 4 and 12 weeks before injection). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07113639, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in